Systaflam

Systaflam is a topical (external-use) combination preparation used for the symptomatic relief of mild-to-moderate musculoskeletal pain. It combines a topical NSAID (diclofenac diethylamine) with a topical muscle relaxant (mephenesin) and three rubefacient/counterirritant agents (menthol, methyl salicylate, and turpentine oil).

Established/Commonly Accepted Uses

• Muscular pain and stiffness, including backache, neck pain, and generalized muscle ache.
• Minor sprains and strains of muscles, ligaments, and tendons (e.g., after minor sports injury or overexertion).
• Muscle spasm associated with musculoskeletal strain.
• Minor joint pain, such as localized pain of osteoarthritis in peripheral joints, as an adjunct to oral therapy or for patients who prefer/require a topical option.

Systaflam is intended for short-term symptomatic relief only; it does not treat the underlying cause of pain. It is not a substitute for medical evaluation of persistent, severe, or worsening pain.

Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil is a fixed-combination topical preparation, typically formulated as a gel, cream, or ointment for external application. It combines diclofenac diethylamine (a topical non-steroidal anti-inflammatory drug, NSAID), mephenesin (a topical skeletal muscle relaxant), menthol, methyl salicylate, and turpentine oil (rubefacient/counterirritant agents). Exact percentage strengths of each component vary by manufacturer and product; consult the specific product label for precise composition.

Systaflam is a multi-ingredient topical analgesic combination intended for external use on the skin over painful muscles and joints. Diclofenac diethylamine, an NSAID, penetrates the skin to provide localized anti-inflammatory and analgesic action. Mephenesin contributes a topical muscle-relaxant effect that may help reduce associated muscle spasm. Menthol, methyl salicylate, and turpentine oil are classic rubefacient/counterirritant ingredients: they produce a sensation of warmth or coolness at the application site that helps distract from and modulate the underlying pain signal, and methyl salicylate also has mild anti-inflammatory activity of its own.

Together, these components are formulated to give combined anti-inflammatory, muscle-relaxant, and counterirritant relief for everyday musculoskeletal aches, sprains, and strains. Systaflam is available in Bangladesh as an externally applied gel/ointment and is intended for short-term, external use only.

Systaflam belongs to the therapeutic class of topical analgesic combinations - specifically a combination of a topical NSAID, a topical muscle relaxant, and rubefacient/counterirritant agents, used for musculoskeletal pain relief.

Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil acts through several complementary mechanisms at the site of application:

• Diclofenac diethylamine is a topical NSAID that inhibits cyclo-oxygenase (COX) enzymes, reducing local prostaglandin synthesis and thereby producing localized anti-inflammatory and analgesic effects at the site of pain.
• Mephenesin is a centrally-acting-type skeletal muscle relaxant that, when applied topically as part of a combination product, is intended to contribute to relief of muscle spasm and tension associated with musculoskeletal pain.
• Menthol stimulates cold-sensitive skin receptors, producing a cooling sensation and mild local analgesic (counterirritant) effect.
• Methyl salicylate is absorbed into the skin and produces a warming counterirritant sensation, along with mild salicylate-related local anti-inflammatory activity.
• Turpentine oil is a rubefacient that increases local blood flow and produces a warming counterirritant sensation, reinforcing the effect of the other counterirritant components.

Systemic absorption of the NSAID and salicylate components through intact skin is generally low with normal, limited-area use, but can increase with application to large body surface areas, under occlusive dressing, with heat, or on broken skin (see Precautions and Warnings).

Apply Systaflam only to intact, unbroken skin over the painful muscle or joint. Wash hands before and thoroughly after application (unless the hands themselves are being treated). Gently massage a thin layer into the skin until absorbed. Avoid contact with the eyes, mouth, nose, and other mucous membranes, and avoid inhaling vapors from methyl salicylate/turpentine oil components in enclosed spaces. Do not apply under an occlusive dressing or with a heating pad. Allow the area to dry before dressing or covering with clothing.

Because Systaflam is applied topically, systemic drug interactions are less likely than with oral therapy, but the following are clinically relevant:

• Oral NSAIDs or aspirin - concurrent use with oral NSAIDs/aspirin increases total systemic NSAID/salicylate exposure and the associated risk of gastrointestinal, renal, and cardiovascular adverse effects; avoid combining without medical guidance.
• Anticoagulants (e.g., warfarin) or antiplatelet agents - the diclofenac and methyl salicylate components, if absorbed systemically in significant amounts (e.g., with extensive or prolonged use), may theoretically add to bleeding risk; use with caution and medical supervision in patients on these medicines.
• Other topical products applied to the same skin area (e.g., other rubefacients, salicylate-containing products) - combining increases the risk of local irritation and additive systemic salicylate absorption; avoid layering such products.

Most adverse effects of Systaflam are local, related to its NSAID, counterirritant, and rubefacient components:

• Local burning, stinging, warmth, or tingling sensation at the application site (common and often expected with counterirritant use).
• Redness, itching, or mild contact dermatitis.
• Dryness or peeling of the skin at the application site.
• Rarely, allergic contact dermatitis, blistering, or photosensitivity reaction.
• Uncommonly, with extensive application or prolonged/excessive use, systemic NSAID-type effects (e.g., mild gastrointestinal upset) may occur due to absorption.

Discontinue use and seek medical advice if severe irritation, blistering, or signs of an allergic reaction develop.

Pregnancy: Systaflam should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use. Systaflam is not recommended during the third trimester of pregnancy because of the topical diclofenac (NSAID) component, which - similar to oral NSAIDs - carries a theoretical risk of premature closure of the fetal ductus arteriosus and other complications with significant systemic exposure, even though topical absorption is generally low.

Lactation: There is limited data on the passage of these components into breast milk after topical use. As a precaution, breastfeeding mothers should use the smallest effective amount, avoid applying Systaflam to the chest/breast area, and consult a physician before use, particularly for prolonged or extensive application.

Systaflam is for external use only. Avoid contact with the eyes, mouth, nose, and other mucous membranes; if accidental contact occurs, rinse thoroughly with water. Do not apply to broken, infected, or irritated skin. Do not cover the treated area with an occlusive/airtight dressing and do not use with a heating pad, as this increases absorption and the risk of burns or irritation.

Avoid application over large areas of the body or for prolonged periods without medical guidance, since increased systemic absorption of the NSAID and salicylate components (particularly relevant in children, the elderly, or with frequent/heavy use) carries the same cardiovascular, gastrointestinal, and renal risks associated with systemic NSAID/salicylate exposure. Wash hands thoroughly after application (unless the hands are the treated area). Avoid combining with oral NSAIDs or aspirin, or with other topical rubefacient/salicylate products on the same area, without medical advice. Use caution in patients with known hypersensitivity to aspirin/NSAIDs, asthma triggered by NSAIDs, or bleeding disorders/anticoagulant therapy. Turpentine oil is flammable and irritant; keep the product away from open flame and avoid inhaling concentrated vapors in enclosed spaces. Discontinue use and consult a physician if excessive skin irritation, rash, or other signs of intolerance occur.

Local overdose/excessive application: Applying too much Systaflam, too frequently, or over too large an area may cause marked local irritation, burning, redness, or blistering. If this occurs, wash the area with water, stop use, and seek medical advice if irritation is severe or persistent.

Accidental ingestion: If Systaflam is accidentally swallowed (especially by a child), seek immediate medical attention or contact a poison control center/emergency services right away, as the methyl salicylate and diclofenac components can cause serious salicylate/NSAID toxicity if ingested in quantity. Do not attempt home treatment or induce vomiting unless specifically instructed by a medical professional or poison control.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed and away from open flame or heat sources, as the turpentine oil component is flammable. Keep out of reach of children.

Children: Safety and efficacy of Systaflam in young children have not been well established; it is generally not recommended below the age stated on the product label (commonly under 12 years) unless a physician directs otherwise, and only with a smaller, closely supervised amount if used.

Elderly: No specific dose adjustment is generally required for topical use, but elderly patients with reduced skin integrity or on systemic NSAIDs/anticoagulants should use with caution due to a theoretically higher risk of systemic absorption and interaction (see Interactions).

Renal or hepatic impairment: Topical use generally results in low systemic exposure, but patients with significant renal or hepatic impairment should use Systaflam cautiously and avoid large-area or prolonged application, given the systemic NSAID/salicylate risks that apply if absorption is increased.

Athletes/occupational use: May be used for minor exercise-related muscular aches, but persistent or severe pain, or pain following significant injury, should be medically evaluated rather than self-treated.

Systaflam is intended for short-term symptomatic use, typically up to 7 days for minor aches, sprains, or strains. If pain, swelling, or stiffness persists beyond 7 days, worsens, or is accompanied by fever or signs of infection, discontinue use and consult a physician rather than continuing self-treatment.

Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil combines agents from several drug classes: a topical Non-Steroidal Anti-Inflammatory Drug (NSAID) - diclofenac diethylamine; a topical skeletal muscle relaxant - mephenesin; and topical rubefacients/counterirritants - menthol, methyl salicylate, and turpentine oil.

Diclofenac Diethylamine + Mephenesin + Menthol + Methyl Salicylate + Turpentine Oil works through the combined local action of an anti-inflammatory NSAID (diclofenac diethylamine), a muscle-relaxant agent (mephenesin), and counterirritant/rubefacient agents (menthol, methyl salicylate, turpentine oil) that create warming/cooling sensations and increase local blood flow. See Pharmacology for the mechanism of each individual component.

Systaflam is generally not recommended for children below the age specified on the product label (commonly under 12 years of age) because safety and efficacy in this age group have not been well established, and children have proportionally greater skin surface area relative to body weight, increasing the risk of systemic NSAID/salicylate absorption and toxicity. If a physician directs use in an older child, only a small amount should be applied to a limited area, avoiding occlusion and heat, and a parent/guardian should supervise application and keep the product out of the child's reach to prevent accidental ingestion.